Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T20:03:55.373Z.
Calculation as of: 2026-10-06T20:03:55.373Z.
Quote observation: 2026-10-06T19:59:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7a98ef6549bf85b46c4ba181efc1584300b0c5a2a31302d891700dc780dc00a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2003-11-19.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
EBITDA YIELD AVG TTM
N/A
EBITDA YIELD AVG 3Y
N/A
EBITDA YIELD AVG 5Y
N/A
EBITDA YIELD AVG 10Y
N/A
EBITDA YIELD AVG 15Y
N/A
EBITDA YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Pluri Inc.
Market Cap
$10.68M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Pluri Inc. (PLUR) | $10.68M | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.94M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.38M | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A |
| BioVie Inc. (BIVI)vs › | $11.01M | N/A |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.12M | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.15M | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.13M | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.29M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA YIELD |
|---|---|
| 2003-11-19 | 0.10% |
| 2003-11-18 | 0.10% |
| 2003-11-17 | 0.09% |
| 2003-11-14 | 0.10% |
| 2003-11-13 | 0.09% |
| 2003-11-12 | 0.10% |
| 2003-11-11 | 0.10% |
| 2003-11-10 | 0.10% |
| 2003-11-07 | 0.10% |
| 2003-11-06 | 0.09% |
| 2003-11-05 | 0.09% |
| 2003-11-04 | 0.09% |
| 2003-11-03 | 0.10% |
| 2003-10-31 | 0.09% |
| 2003-10-30 | 0.10% |
| 2003-10-29 | 0.10% |
| 2003-10-28 | 0.09% |
| 2003-10-27 | 0.09% |
| 2003-10-24 | 0.08% |
| 2003-10-23 | 0.08% |
| 2003-10-22 | 0.09% |
| 2003-10-21 | 0.09% |
| 2003-10-20 | 0.09% |
| 2003-10-17 | 0.09% |
| 2003-10-16 | 0.08% |
| 2003-10-15 | 0.09% |
